BioSpace News Archive

Novamind Inc., a leading mental health company specialized in psychedelic medicine, reported its fiscal third-quarter results for the three and nine months ended March 31st, 2021.

LUMINOS-101 and LUMINOS-102 study designs to be presented Preclinical data for PVSRIPO in combination with anti-PD-1 immune checkpoint inhibitors to be presented

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the appointment of Georgia Erbez and Elizabeth (Liz) Cermak to its Board of Directors. Ms. Erbez and Ms. Cermak are accomplished, experienced life science executives and board directors.

Century Therapeutics , a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Alessandro Riva , M.D., and Kimberly Blackwell, M.D., as new Independent Directors.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced important findings from a podium presentation on DSUVIA

AHI’s CompleteScan Technology to be Integrated into European Psychological, Psychiatric and Wellbeing Platform to Address Chronic Disease and Obesity Risk

ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, today announced that Gregory F. Keenan, M.D., has been appointed as chief medical officer (CMO), bringing more than 20 years of experience in the development and commercialization of small molecules and biologics.

Selexis Appoints Roland Hoffmann- Hecht, PhD, as Chief Business Officer Business Development Executive in Biologics Drug Development and Manufacturing Brings More than 25 Years of Biopharmaceutical Industry Experience

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the company will host a conference call and webcast to review updated 90-day efficacy, safety and pharmacokinetic data from its ongoing multicenter Phase 1 clinical trial of JSP191

Harrow Health, Inc., an ophthalmic-focused healthcare company, announced the launch of its newly redesigned corporate and investor website, harrowinc.com.